Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Therapeutic drug monitoring uncovering incorrect antiretroviral drug intake in a patient with swallowing difficulties.

Created on 20 Sep 2026

Authors

Giorgia Carrozzo, Dario Cattaneo, Andrea Giacomelli, Andrea Gori, Anna Lisa Ridolfo, Cristina Gervasoni, Maria Vittoria Cossu

Published in

IDCases. Volume 46. Pages e02757. Epub Sep 09, 2026.

Abstract

A woman living with HIV reported swallowing difficulties that interfered with oral antiretroviral therapy. Treatment with darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®) was initiated, with the patient choosing to chew the tablet before swallowing because of her swallowing difficulties. Therapeutic drug monitoring, performed because of this non-standard administration, revealed unexpectedly low darunavir trough concentrations despite reported adherence and maintained virological suppression. A structured pharmacological assessment revealed that the patient had been consistently taking the medication in the fasting state, despite initial counselling to take it with food. After correction of the drug intake conditions, darunavir exposure increased to therapeutic levels. This case highlights the clinical value of therapeutic drug monitoring in identifying medication intake errors and optimising antiretroviral therapy in patients with swallowing difficulties.

PMID:
42763503
Bibliographic data and abstract were imported from PubMed on 20 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement